Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma
In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognos...
Gespeichert in:
Veröffentlicht in: | Pathology oncology research 2011-09, Vol.17 (3), p.605-611 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 611 |
---|---|
container_issue | 3 |
container_start_page | 605 |
container_title | Pathology oncology research |
container_volume | 17 |
creator | Matsumoto, Naoki Umezawa, Takashi Sasaki, Toru Nakajima, Kuninobu Kanetsuna, Yukiko Sasaki, Hiroshi |
description | In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%,
P
= 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC. |
doi_str_mv | 10.1007/s12253-010-9356-5 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_884848230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2788361671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-b03a54fb698ec24ea263c9a55f9da6ca83ea0f2788a9ab4a2039fadb0917e2eb3</originalsourceid><addsrcrecordid>eNp1kUtLxDAUhYMovn-AGwm4cFXNo0mbpRQdBVEXo9twm7kdK510TFrBf290RhHBZJHc3O-cXDiEHHF2xhkrziMXQsmMcZYZqXSmNsguV1JkomTFZroLbrLcKL1D9mJ8YUmjjd4mO4KLIteF3CWh6lrfOugo-Bl9CP3c93FoHX2CbkTaN3R4xvSOEb37qm9CwPnYQaCTFvxA70bXYaoq7LpIW0-XU07v3yCkLq1-WrSC4FrfL-CAbDXQRTxcn_vk8epyWl1nt_eTm-riNnNSyCGrmQSVN7U2JTqRIwgtnQGlGjMD7aCUCKwRRVmCgToHwaRpYFYzwwsUWMt9crryXYb-dcQ42EUbXRoFPPZjtGWZpy0kS-TJH_KlH4NPw1meVqkU03mi-IpyoY8xYGOXoV1AeLec2c887CoPm_Kwn3lYlTTHa-exXuDsR_EdQALECoip5ecYfn39r-sH8Y6VDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1111855064</pqid></control><display><type>article</type><title>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Matsumoto, Naoki ; Umezawa, Takashi ; Sasaki, Toru ; Nakajima, Kuninobu ; Kanetsuna, Yukiko ; Sasaki, Hiroshi</creator><creatorcontrib>Matsumoto, Naoki ; Umezawa, Takashi ; Sasaki, Toru ; Nakajima, Kuninobu ; Kanetsuna, Yukiko ; Sasaki, Hiroshi</creatorcontrib><description>In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%,
P
= 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.</description><identifier>ISSN: 1219-4956</identifier><identifier>EISSN: 1532-2807</identifier><identifier>DOI: 10.1007/s12253-010-9356-5</identifier><identifier>PMID: 21274673</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adenocarcinoma, Clear Cell - pathology ; Adenocarcinoma, Clear Cell - surgery ; Adult ; Aged ; Aged, 80 and over ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Nucleus - pathology ; Female ; Humans ; Immunology ; Middle Aged ; Neoplasm Staging ; Oncology ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Pathology ; Prognosis ; Retrospective Studies ; Survival Rate</subject><ispartof>Pathology oncology research, 2011-09, Vol.17 (3), p.605-611</ispartof><rights>Arányi Lajos Foundation 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c323t-b03a54fb698ec24ea263c9a55f9da6ca83ea0f2788a9ab4a2039fadb0917e2eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12253-010-9356-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12253-010-9356-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21274673$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsumoto, Naoki</creatorcontrib><creatorcontrib>Umezawa, Takashi</creatorcontrib><creatorcontrib>Sasaki, Toru</creatorcontrib><creatorcontrib>Nakajima, Kuninobu</creatorcontrib><creatorcontrib>Kanetsuna, Yukiko</creatorcontrib><creatorcontrib>Sasaki, Hiroshi</creatorcontrib><title>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</title><title>Pathology oncology research</title><addtitle>Pathol. Oncol. Res</addtitle><addtitle>Pathol Oncol Res</addtitle><description>In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%,
P
= 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.</description><subject>Adenocarcinoma, Clear Cell - pathology</subject><subject>Adenocarcinoma, Clear Cell - surgery</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Nucleus - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunology</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Pathology</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><issn>1219-4956</issn><issn>1532-2807</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUtLxDAUhYMovn-AGwm4cFXNo0mbpRQdBVEXo9twm7kdK510TFrBf290RhHBZJHc3O-cXDiEHHF2xhkrziMXQsmMcZYZqXSmNsguV1JkomTFZroLbrLcKL1D9mJ8YUmjjd4mO4KLIteF3CWh6lrfOugo-Bl9CP3c93FoHX2CbkTaN3R4xvSOEb37qm9CwPnYQaCTFvxA70bXYaoq7LpIW0-XU07v3yCkLq1-WrSC4FrfL-CAbDXQRTxcn_vk8epyWl1nt_eTm-riNnNSyCGrmQSVN7U2JTqRIwgtnQGlGjMD7aCUCKwRRVmCgToHwaRpYFYzwwsUWMt9crryXYb-dcQ42EUbXRoFPPZjtGWZpy0kS-TJH_KlH4NPw1meVqkU03mi-IpyoY8xYGOXoV1AeLec2c887CoPm_Kwn3lYlTTHa-exXuDsR_EdQALECoip5ecYfn39r-sH8Y6VDQ</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>Matsumoto, Naoki</creator><creator>Umezawa, Takashi</creator><creator>Sasaki, Toru</creator><creator>Nakajima, Kuninobu</creator><creator>Kanetsuna, Yukiko</creator><creator>Sasaki, Hiroshi</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</title><author>Matsumoto, Naoki ; Umezawa, Takashi ; Sasaki, Toru ; Nakajima, Kuninobu ; Kanetsuna, Yukiko ; Sasaki, Hiroshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-b03a54fb698ec24ea263c9a55f9da6ca83ea0f2788a9ab4a2039fadb0917e2eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adenocarcinoma, Clear Cell - pathology</topic><topic>Adenocarcinoma, Clear Cell - surgery</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Nucleus - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunology</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Pathology</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsumoto, Naoki</creatorcontrib><creatorcontrib>Umezawa, Takashi</creatorcontrib><creatorcontrib>Sasaki, Toru</creatorcontrib><creatorcontrib>Nakajima, Kuninobu</creatorcontrib><creatorcontrib>Kanetsuna, Yukiko</creatorcontrib><creatorcontrib>Sasaki, Hiroshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology oncology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsumoto, Naoki</au><au>Umezawa, Takashi</au><au>Sasaki, Toru</au><au>Nakajima, Kuninobu</au><au>Kanetsuna, Yukiko</au><au>Sasaki, Hiroshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma</atitle><jtitle>Pathology oncology research</jtitle><stitle>Pathol. Oncol. Res</stitle><addtitle>Pathol Oncol Res</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>17</volume><issue>3</issue><spage>605</spage><epage>611</epage><pages>605-611</pages><issn>1219-4956</issn><eissn>1532-2807</eissn><abstract>In the early stages of epithelial ovarian cancer, histopathological grading is important. However, the grading of ovarian clear cell carcinoma (OCCC) remains controversial. We aimed to identify irregular giant nuclear cells (IGNCs) by a simple method in clinical practice, and to evaluate the prognostic value of IGNCs in pT1 OCCC. Eighty-seven pT1 OCCC patients who underwent initial surgery at Jikei University Kashiwa Hospital, Chiba, Japan, were retrospectively assessed. Paraffin-embedded tissue sections (PTSs) stained with hematoxylin and eosin were reviewed. Giant nuclear cells (GNCs) were defined as cells with a nuclear length of more than twice the median nuclear length. GNCs with irregular nuclear circumferences were defined as IGNCs. Cases where one or more GNCs existed and where IGNCs accounted for >10% of the GNCs were classified as IGNC-positive. We also attempted to identify IGNCs on touch imprint cytology smears (TICSs). Among the 87 cases, 68 were IGNC-negative and 19 were IGNC-positive. The 5-year disease-free and overall survival rates were 88.9% and 90.3% in the total patients, 98.3% and 100% in the IGNC-negative group, and 59.7% and 62.0% in the IGNC-positive group, respectively. These survival rates were significantly lower in the IGNC-positive group than in the IGNC-negative group (adjusted hazard ratio = 14, 95% confidence interval = 2.7–124 and adjusted hazard ratio = 25, 95% confidence interval = 2.9–768, respectively). Prognostic differences were not identified for other factors. IGNC identification on 28 available TICSs predicted IGNC identification on PTSs (sensitivity = 50.0%, specificity = 100%,
P
= 0.007). The presence of IGNCs has clinical and prognostic value for pT1 OCCC.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>21274673</pmid><doi>10.1007/s12253-010-9356-5</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1219-4956 |
ispartof | Pathology oncology research, 2011-09, Vol.17 (3), p.605-611 |
issn | 1219-4956 1532-2807 |
language | eng |
recordid | cdi_proquest_miscellaneous_884848230 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adenocarcinoma, Clear Cell - pathology Adenocarcinoma, Clear Cell - surgery Adult Aged Aged, 80 and over Biomedical and Life Sciences Biomedicine Cancer Research Cell Nucleus - pathology Female Humans Immunology Middle Aged Neoplasm Staging Oncology Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Pathology Prognosis Retrospective Studies Survival Rate |
title | Clinical and Prognostic Value of the Presence of Irregular Giant Nuclear Cells in pT1 Ovarian Clear Cell Carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T12%3A36%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20Prognostic%20Value%20of%20the%20Presence%20of%20Irregular%20Giant%20Nuclear%20Cells%20in%20pT1%20Ovarian%20Clear%20Cell%20Carcinoma&rft.jtitle=Pathology%20oncology%20research&rft.au=Matsumoto,%20Naoki&rft.date=2011-09-01&rft.volume=17&rft.issue=3&rft.spage=605&rft.epage=611&rft.pages=605-611&rft.issn=1219-4956&rft.eissn=1532-2807&rft_id=info:doi/10.1007/s12253-010-9356-5&rft_dat=%3Cproquest_cross%3E2788361671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1111855064&rft_id=info:pmid/21274673&rfr_iscdi=true |